Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medicines Company halts heart drug trial
Clevelox is an investigational drug undergoing phase III clinical trials as an agent to reduce blood pressure in cardiac surgery. Trial enrollment was halted after a planned interim
Clevelox is an investigational drug undergoing phase III clinical trials as an agent to reduce blood pressure in cardiac surgery. Trial enrollment was halted after a planned interim
The Therapeutic Goods Administration (TGA) defines orphan drug products as “drugs, vaccines or in vivo diagnostic agents which physicians use to treat, prevent or diagnose rare diseases.” The
Under the terms of the agreement, Tanox will receive all tissue factor antagonist assets from Sunol, including anti-tissue factor monoclonal antibodies and related technologies and intellectual properties, as
The two studies were designed to evaluate whether adding Targretin (bexarotene) capsules to front-line cisplatin/vinorelbine or carboplatin/paclitaxel chemotherapy extends the survival of patients with advanced non-small cell lung
The agreement covers the development and commercialization of most of Dr Reddy’s abbreviated new drug applications (ANDAs) to be filed in 2004-05 and 2005-06. Under the terms of
The TriActiv System, according to Kensey Nash, is an embolic protection device used during percutaneous coronary intervention of diseased saphenous vein grafts. It aims to prevent material or
A total of 450 healthy adults will be enrolled at sites in the US. The clinical sites are part of the National Institute of Allergy and Infectious Diseases
The study, which enrolled 258 chronic obstructive pulmonary disease (COPD) patients, evaluated Icos’ phosphodiesterase 4 (PDE4) inhibitor, IC485, at three doses compared to placebo. “While we are disappointed
The company will concentrate its efforts on a planned phase II/III trial in chronic lymphocytic leukemia (CLL) and a planned a phase I/II trial in HIV, but will
These results follow the previously announced effectiveness on Neuroblastoma cells and are the first of a current series of continuing in vitro tests of PhG-alpha1 targeting a range